A carregar...
Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study
BACKGROUND: Evocalcet has been developed as a new calcimimetic agent for hemodialysis (HD) patients with secondary hyperparathyroidism (HDSHPT), eliciting fewer gastrointestinal symptoms and drug interactions. We evaluated the efficacy, safety, and optimal starting dose of evocalcet in HDSHPT. METHO...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6209414/ https://ncbi.nlm.nih.gov/pubmed/30379826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0204896 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|